Abstract
Imipenem/cilastatin (IPM/CS) is an antibiotic that has been applied as a temporary embolic agent in musculoskeletal (MSK) embolotherapy. While the therapeutic potential of IPM/CS as an embolic agent for pain relief has been demonstrated in osteoarthritis (OA) and tendinopathy, its characteristics, mechanism of action, and the manner in which a temporary embolic induces longstanding clinical effects remain unclear. This commentary summarizes what is known about IPM/CS, bridges knowledge gaps, and offers possible mechanisms by which its use could lead to MSK pain relief.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
